Friedenthal Financial Raises Stock Holdings in Insulet Corporation (NASDAQ:PODD)

Friedenthal Financial raised its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 1,400.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 3,301 shares of the medical instruments supplier's stock after buying an additional 3,081 shares during the period. Friedenthal Financial's holdings in Insulet were worth $867,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in Insulet during the fourth quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet during the fourth quarter worth about $42,000. SRS Capital Advisors Inc. raised its holdings in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares during the last quarter. Assetmark Inc. raised its holdings in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares during the last quarter. Finally, Coppell Advisory Solutions LLC raised its holdings in shares of Insulet by 135.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after acquiring an additional 162 shares during the period.

Insulet Stock Up 0.5%

Shares of NASDAQ:PODD traded up $1.36 during trading hours on Friday, reaching $303.15. The stock had a trading volume of 1,539,107 shares, compared to its average volume of 715,791. Insulet Corporation has a 1 year low of $173.00 and a 1 year high of $329.33. The firm's 50 day moving average is $291.86 and its 200-day moving average is $276.25. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The stock has a market capitalization of $21.34 billion, a price-to-earnings ratio of 54.52, a P/E/G ratio of 2.71 and a beta of 1.37.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet's quarterly revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm earned $0.73 earnings per share. Research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on PODD shares. The Goldman Sachs Group initiated coverage on Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Barclays upped their price target on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price objective (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Royal Bank Of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price for the company. Finally, Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price for the company in a research report on Tuesday, May 13th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $321.00.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.